Time filter

Source Type

Ghogomu S.M.,University of Buea | Ngolle N.E.,University of Buea | Mouliom R.N.,Diabetes and Hypertension Clinic | Asa B.F.,University of Buea
Genetics and Molecular Research | Year: 2016

The association of the methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism and essential hypertension has been reported but with controversial results in diverse populations in Asia and Europe, thereby suggesting a dependency on ethnicity. The aim of this study was to investigate the association between the MTHFR C677T polymorphism and essential hypertension in a Cameroonian population (Bantu ethnic group) of the South West Region. Analysis of anthropometric and biochemical data in hypertensive and normotensive subjects revealed that age, systolic blood pressure, diastolic blood pressure, low-density lipoprotein cholesterol, serum total cholesterol, and triglycerides are independent risk factors for essential hypertension. Substitution of thymine for cytosine at position 667 of the MTHFR gene was determined by polymerase chain reaction-restriction fragment length polymorphism. Genotype frequencies were found to be 7.3% CC, 58.5% CT, and 34.1% TT for hypertensive subjects compared to 90.0% CC, 10.0% CT, and 0.0% TT for normotensives. Allele frequencies were obtained as 36.6% C and 63.4% T for hypertensive subjects and 95.0% C and 5.0% T for normotensive subjects. These results reveal that the T allele predisposes individuals to hypertension. Therefore, there is an association between variants of the MTHFR gene and hypertension in Cameroonian patients from the South West region. © FUNPEC-RP. Source

Ghogomu S.M.,University of Buea | Atanga R.,University of Buea | Mungwa S.T.,University of Buea | Muliom R.N.,Diabetes and Hypertension Clinic
International Journal of Clinical and Experimental Medicine | Year: 2016

There has been inconsistent association of the angiotensin II type 1 receptor (ATR1) gene polymorphism and hypertension among various populations in different countries. With respect to these controversial reports, this study was designed to investigate if substitution of A for C at position 1166 (A1166C) in the ATR1 gene could be at the basis of hypertension in the Cameroonian population of the South West Region (SWR). Analysis of anthropometric data revealed that systolic and diastolic blood pressures as well as age could be classified as independent risk factors of essential hypertension. Eighty-six subjects (36 hypertensive and 50 normotensive subjects) were recruited from SWR and genotyped for A1166C polymorphism of ATR1 gene by restriction fragment length polymorphism. Genotype distribution was found to be 91.7% AA, 2.8% AC, and 5.6% CC for hypertensive subjects and 86% AA, 6.0% AC and 8.0% CC for normotensive subjects. Allele distribution was 93% A, 7% C for hypertensive subjects as against 89% A and 11% C for normotensive subjects. Analysis of results indicated that no significant differences in ATR1 genotype distribution (P > 0.05) and allele frequencies (P > 0.05) exist between hypertensive and normotensive subjects in the studied population. Also there was no significant difference in genotype distribution with sex. The study therefore concludes that there is lack of association between variants of the ATR1 gene and hypertension in Cameroonians of the SWR. © 2016, E-Century Publishing Corporation. All rights reserved. Source

Phimda K.,Diabetes and Hypertension Clinic | Chotnoparatpat P.,Bangkok Metropolitan Administration Medical College
International Journal of Collaborative Research on Internal Medicine and Public Health | Year: 2012

Introduction: The national health examination survey in Thailand determined that T2DM and dyslipidemia were probable risk factors resulting in higher rate of uncontrolled hypertension. This had been reported with controlled rate as low as 15%. The authors investigated if the choice of antihypertensive agents render better blood pressure control in Thai hypertensive patients. Objective: To assess the blood pressure (BP) lowering efficacy of Perindopril/indapamide Fixed Dose Combination (P/I FDC), as an antihypertensive of choice in Thai hypertensive patients with multiple co-morbidities and risk factors. Method: A prospective consecutive open-blind evaluation short-term follow-up was initiated with Perindopril 4 mg/Indapamide 1.25 mg Fixed Dose Combination (P/I FDC) among 1,364 Thai hypertensive patients, as newly diagnosed monotherapy, or switched from either inhibitors of angiotensin converting enzyme or angiotensin receptor blocking agents, with addition of either calcium channel blockers of beta-blockers allowed in a multi-center trial hypertensive patients with safety monitoring program demanded by Thai health authority. Result: After 3 months of treatment, the SBP/DBP of patients receiving P/I FDC-based treatment (mean ± SD), [95% CI] was 131.6±9.6 [131.0-132.1] /78.7 ±7.1 [78.3-79.0] mmHg resulting from SBP/DBP reduction of 26.6/11.8 mmHg respectively. In the overall cohort, only 9.7% of patients required additional antihypertensive agents. The authors founded that in newly diagnosed stage 2 hypertensive patients, hypertensive patients with diagnosed dyslipidemia, and with diagnosed T2DM, P/I FDC mono-therapy or in combination effectively reduced SBP/DBP by 33.9/16.0 mmHg, 30.7/12.8 mmHg and 23.5/11.0 mmHg respectively. Overall blood pressure normalization with P/I FDC with SBP/DBP<130/80 mmHg and <140/90 mmHg were 48.2% and 91.4% respectively which were above earlier reported in Thai hypertensive patients. P/I FDC was well tolerated by patients, with a reported cough incidence of 5.1 %. Conclusion: The choice of antihypertensive agents is a critical factor for the control of hypertension. P/I FDC is an effective antihypertensive agent in Thai hypertensive patients for uncontrolled hypertension. It is effective in both newly diagnosed stage I, stage II hypertension and among patients with diagnosed Type 2 Diabetes and dyslipidemia. In daily clinical practice, P/I FDC should be recommended as the first choice antihypertensive among uncontrolled Thai hypertensive patients. Source

Discover hidden collaborations